Adrenal medullary hyperplasia

Summary

Adrenal medullary hyperplasia (MONDO:0006077) is a disease. A subtype of hyperplasia — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Prevalence: <1 / 1 000 000 (Worldwide) [Orphanet-validated]

Clinical features

Epidemiology

Prevalence records

2 prevalence record(s), Orphanet:

Type	Class	Value	Geography	Validation
Cases/families		66	Worldwide	Validated
Point prevalence	<1 / 1 000 000		Worldwide	Validated

Identifiers

Disease identifiers

Field	Value
Canonical name	adrenal medullary hyperplasia
Mondo ID	MONDO:0006077
EFO	EFO:1000076
Orphanet	688649
NCIT	C35838
UMLS	C1332177
MedGen	231356
GARD	0027350
Anatomy (UBERON)	UBERON:0001236
Is cancer (heuristic)	no

Also known as: adrenal medulla hyperplasia

Disease family

This is a subtype of hyperplasia. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › hyperplasia › adrenal medullary hyperplasia

Related subtypes (13): atypical endometrial hyperplasia, atypical lobular breast hyperplasia, C-cell hyperplasia, columnar cell hyperplasia of the breast, complex endometrial hyperplasia, endometrial hyperplasia without atypia, parathyroid hyperplasia, simple endometrial hyperplasia, usual ductal breast hyperplasia, focal epithelial hyperplasia, benign prostatic hyperplasia, neuroendocrine cell hyperplasia of infancy, urothelial hyperplasia

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.